iifl-logo-icon 1

Beta Drugs Ltd Share Price

1,301.05
(0.04%)
Jul 22, 2024|03:33:13 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,260
  • Day's High1,320
  • 52 Wk High1,595
  • Prev. Close1,300.55
  • Day's Low1,260
  • 52 Wk Low728
  • Turnover (lac)106.68
  • P/E56.99
  • Face Value10
  • Book Value0
  • EPS22.82
  • Mkt. Cap (Cr.)1,250.8
  • Div. Yield0
No Records Found

Beta Drugs Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,260

Prev. Close

1,300.55

Turnover(Lac.)

106.68

Day's High

1,320

Day's Low

1,260

52 Week's High

1,595

52 Week's Low

728

Book Value

0

Face Value

10

Mkt Cap (₹ Cr.)

1,250.8

P/E

56.99

EPS

22.82

Divi. Yield

0

Beta Drugs Ltd Corporate Action

1 Sep 2023

12:00 AM

AGM

Announcement Date: 01 Sep, 2023

arrow

1 Sep 2023

12:00 AM

BookCloser

arrow

8 Jul 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Beta Drugs Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Beta Drugs Ltd SHAREHOLDING SNAPSHOT

23 Jul, 2024|05:38 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 66.73%

Foreign: 0.00%

Indian: 66.73%

Non-Promoter- 0.38%

Institutions: 0.38%

Non-Institutions: 32.88%

Custodian: 0.00%

Share Price

Beta Drugs Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

9.61

9.61

9.61

9.61

Preference Capital

0

0

0

0

Reserves

86.64

67.85

53.8

46.83

Net Worth

96.25

77.46

63.41

56.44

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Revenue

79.45

58.04

50.56

yoy growth (%)

14.79

21.4

Raw materials

-43.44

-30.44

-27.18

As % of sales

54.68

52.44

53.75

Employee costs

-6.05

-3.41

-1.88

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2019Mar-2018

Profit before tax

9.88

7.46

6.83

Depreciation

-5.26

-2.57

-2.42

-1.85

Tax paid

-2.9

0.24

-0.07

Working capital

6.55

5.39

-7.9

17.2

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2019Mar-2018

Growth matrix (%)

Revenue growth

14.79

21.4

Op profit growth

8.99

29.86

EBIT growth

4.45

29.28

Net profit growth

14.05

58.42

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

295.71

227.11

183.84

116.12

90.81

Excise Duty

0

0

0

0

0

Net Sales

295.71

227.11

183.84

116.12

90.81

Other Operating Income

0

0

0

0

0

Other Income

1.36

0.75

0.76

0.5

0.41

Beta Drugs Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.65

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,519.8

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.5

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.45

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,636

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Beta Drugs Ltd

Management

Register Office

Registrar Office

Whole-time Director

Balwant Singh.

Joint Managing Director

Varun Batra

Chairperson & M D

Rahul Batra

Independent Director

Manmohan Khanna

Independent Director

Rohit Parti

Company Sec. & Compli. Officer

Rajni Brar

Whole-time Director

Seema Chopra

Whole-time Director

Ashutosh Shukla

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to public limited company and the name of the company was changed to Beta Drugs Limited on August 11, 2017 Beta Drugs is a part of Adley Group. Adley Group was founded in the year 1985, by its promoter Vijay Batra, who has more than twenty five years of experience in manufacture of pharmaceutical products in India. The Company is a pharmaceutical formulation manufacturing company engaged in developing, manufacturing and marketing of drug products for domestic and international customers. The Promoter Vijay Batra, took over the company from Kiran Goyal, Deepak Kumar Prince Bharti and Rohit Bansal in the year 2014. The company is primarily engaged in the manufacturing of oncology products. The Companys products range from anti-cancer tablets, capsules, injections and lyophilized injections. The Company started production of oncology products by manufacturing portfolio of over 35 products which is used for the treatment of various cancer disease. The Company set up the first Oncology Unit in Adley Formulations Pvt Ltd. in 2008. It set up a new state of the art manufacturing facility for oncology formulations in 2014; developed in-house Albumin bound Paclitaxel in 2015; started in-house API Plant - Adley Labs in 2017. In October, 2017, the Company came up with a Public Issue of 22,96,000 Eq
Read More

Company FAQs

What is the Beta Drugs Ltd share price today?

Down Arrow

The Beta Drugs Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is Rs.₹1301.05 today.

What is the Market Cap of Beta Drugs Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Beta Drugs Ltd is ₹1250.80 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Beta Drugs Ltd?

Down Arrow

The PE and PB ratios of Beta Drugs Ltd is 56.99 and 10.78 as of 22 Jul ‘24

What is the 52 Week High and Low of Beta Drugs Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Beta Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Beta Drugs Ltd is ₹728 and ₹1595 as of 22 Jul ‘24

What is the CAGR of Beta Drugs Ltd?

Down Arrow

Beta Drugs Ltd's CAGR for 5 Years at 72.56%, 3 Years at 52.30%, 1 Year at 75.57%, 6 Month at -9.20%, 3 Month at -7.00% and 1 Month at 6.78%.

What is the shareholding pattern of Beta Drugs Ltd?

Down Arrow

The shareholding pattern of Beta Drugs Ltd is as follows:
Promoters - 66.73 %
Institutions - 0.38 %
Public - 32.88 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.